ABSTRACT—Introduction: The aim of this study was to investigate the correlation between plasma sphingosine-1-phosphate (S1P) and ceramide concentrations in sepsis, and the possible mechanisms for altered expression. Methods: Plasma S1P and ceramide concentrations were measured by HPLC-ESI-MS/MS. HLA-DR (human leukocyte antigen-DR) expression on peripheral blood mononuclear cells was examined by flow cytometry. Platelet sphingosine kinases 1/2 (SphK1/2) mRNA expression, protein content, and enzyme activities were determined by qRT-PCR, western blot, and commercial enzyme assay kits, respectively. Results: Compared with healthy and ICU controls, septic patients had significantly decreased plasma S1P but increased ceramide concentrations ($P < 0.05$). S1P concentration was negatively associated with the concentration in the septic patients ($r = -0.36$, $P < 0.05$). Linear regression analysis found that plasma S1P and ceramide were linked not only to sequential (sepsis-related) organ failure assessment (SOFA) score but also to the HLA-DR expression on circulating monocytes. An receiver operating characteristic analysis, including S1P, ceramide, SOFA score and HLA-DR, showed integrated analysis of S1P and ceramide as the better powerful predictors of septic lethality with area under the curve value of 0.95. More importantly, we found the platelet SphKs activities and the expression levels of SphK1 were significantly decreased in septic patients ($P < 0.05$). Linear regression analysis revealed platelet SphKs activity was positively associated with the plasma S1P concentration of the septic patients ($r = -0.41$, $P = 0.02$). Conclusions: Integrated analysis of plasma S1P and ceramide predict septic mortality with high accuracy. The decreased platelet SphK1 expression and subsequent reduced SphKs activity might be responsible for the decreased plasma S1P levels during sepsis.

KEYWORDS—Ceramide, platelet, sepsis, sphingosine kinases 1/2, sphingosine-1-phosphate

INTRODUCTION

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (1). The current criterion for sepsis (Sepsis-3) has been suggested the increase of sequential organ failure assessment (SOFA) ≥2 points from baseline (1). In sepsis, the immune response that is initiated by an invading pathogen fails to return to homeostasis, thus culminating in uncontrolled inflammation and immune suppression, followed by organ dysfunction (2). So far, anti-sepsis treatment modalities are rather limited, and the mortality rate of these patients is approximately 25% to 30%, and even increases from 40% to 50% when shock is present (3, 4). Sepsis remains one of the most pressing public health burdens worldwide.

A main factor affecting sepsis-related mortality is the diagnostic delay that hinders proper treatment (5–7). Recognizing sepsis early improves outcomes of patients (8). Hallmarks for sepsis severity include uncontrolled inflammation and/or immune suppression, endothelial barrier disruption, and organ dysfunction, all of which are potentially regulated by sphingolipid mediators (9, 10). S1P and ceramide are 2 major sphigolipids, which contribute to membrane structure and signaling events that mediate response to stress such as sepsis (11, 12). Ceramide, generated by membrane sphingomyelin (SM) hydrolysis by sphingomyelinases (SMase),

Address reprint requests to Xiangming Fang, MD, Department of Anesthesiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. E-mail: xmfang@zju.edu.cn; Correspondence: Hong Liu, PhD, State Key Laboratory of Drug Research and Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China; E-mail: hliu@simm.ac.cn. Xiao Liang Wu and Jin Chao Hou designed equally to this work.

Authors’ Contributions: X.W. and J.H. designed and performed the research, analyzed the data, and wrote the manuscript; H.L., G.X., X.Z., J.Z., J.W., F.G., and X.F. designed the research, analyzed the data, and corrected the manuscript. All authors read and approved the final manuscript for publication.

Funding Statement: This study was supported by programs from the National Natural Science Foundation of China (No. 815601605); The Major Project of Chinese National for Fundamental Research and Development (2015CB910304); Project funded by China Postdoctoral Science Foundation (No. 2017M612008); Project funded by Zhejiang Postdoctoral Science Foundation, and Zhejiang Medical Science and Technology Program (No. 2015KYA088).

Conflicts of interest: The authors report no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.shockjournal.com).

DOI: 10.1097/SHK.0000000000001229

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Shock Society. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
can act as a bioactive second messenger, or can be metabolized into sphingosine by ceramidases. Sphingosine is phosphorylated by sphingosine kinases 1 and 2 (SphK1/2) to generate S1P (13). There is a selective enrichment of SM in platelet cytoskeletons (13). SM is located in substantial amounts in the outer layer of platelet plasma membranes and is thought to be an important source of plasma S1P and ceramide (14). Ceramide and S1P exhibit opposite biological properties, ceramide promotes cell cycle arrest and apoptosis, whereas S1P exerts a pro-survival and mitogenic activity (13, 15). The inverse behaviors of both markers led us to compare the predictive value of S1P and ceramide analysis in sepsis-related mortality. In this study, we sought to determine whether serum S1P and ceramide levels are altered in sepsis based on the sepsis-3 definition; the predictive role of S1P and ceramide in the outcome of sepsis; and the possible reasons for the altered plasma-S1P and ceramide levels during sepsis.

METHODS

Study participants

Patients who met the clinical criteria for sepsis-3 were screened for eligibility within the first 24 h after they were admitted to the intensive care unit (ICU) of Zhejiang University Hospitals between September 2016 and May 2017 (16). A total of 33 septic patients were enrolled into the study. Patients were included if they had known or suspected infection plus an increase in the SOFA (sepsis-related) score of 2 points or more for organ dysfunction. Exclusion criteria were pregnancy or breast feeding, age younger than 18 yrs or older than 80 yrs, human immunodeficiency virus infection, treatment with corticosteroids or chemotherapy within 4 weeks, and inability to provide informed consent (17). Nineteen non-septic patients but in critical conditions with systemic inflammatory response syndrome (SIRS) were recruited as controls, such as trauma and severe acute pancreatitis. The clinical data, including SOFA score, cause of sepsis, microbial culture result, length of ICU stay, and mortality during the 28-day study period, were recorded (Table 1). Thirty-one healthy donors with no medical problems in the medical examination center of the affiliated hospitals of Zhejiang University were also included as controls. The study protocol was approved by the local institutional review board, and informed consent was obtained from all study participants or their surrogates.

S1P and ceramide measurement

S1P (C-18) and ceramide (C-16) in plasma isolated from study participants were quantified with high performance liquid chromatography-electrospray ionization tandem mass spectrometry/mass spectrometry as described before (17). Calibration curves for S1P measurement was prepared using 6 different concentrations ranging from 0 ng/mL to 10,000 ng/mL, and for ceramide was prepared using 6 different concentrations ranging from 0 ng/mL to 500 ng/mL. FTY720 was used as an internal reference for each sample. The samples, including 25 μL of serum, 25 μL of internal standard, 25 μL of acetonitrile, and 25 μL of methanol, were mixed for 30 s on a rotator at room temperature and centrifuged at 18,400 g for 5 min. The supernatant was transferred to an autosampler HPLC vial, 8 μL of which was then injected into the HPLC system for analysis (Agilent Technologies, Santa Clara, CA). Quantification of the S1P and ceramide peaks was calculated from the standard calibration curve.

Peripheral blood mononuclear cells isolation

Peripheral blood was collected at day 1 of ICU admission. Monocytes were prepared as previously described (16). In brief, the blood was diluted with phosphate buffered saline (PBS). The diluted blood was then added gently to the top of the Ficoll solution (Sigma-Aldrich, St. Louis, MO; ID: F5415) and then centrifuged at 698 g for 20 min. The middle layer containing the mononuclear cells was then aspirated and washed twice with PBS. The cell pellets were resuspended in 1 mL Roswell Park Memorial Institute 1640 medium (Thermo Fisher Scientific, Rockford, IL) containing 10% fetal bovine serum (Morerate BioTech, Bulimba, Australia), and cultured in 12-well plates for 0.5 h in a humidified atmosphere at 37°C in 5% CO₂ and 95% air. The adherent monocytes were washed three times with PBS, and then were collected for flow cytometry analysis.

Peripheral blood platelet isolation

Platelets were prepared as previously described (18). Briefly, whole blood was collected into acid-citrate-dextrose (ACD) with 5 mM ethylenediamine tetraacetic acid (ACD: blood = 1:9, v/v). Platelet-rich plasma was collected by differential centrifugation at 160 g for 15 min. Platelets were isolated by centrifugation at 650 g for 15 min and then washed five times in PBS.

Flow cytometry analysis

In the case of blood samples, red blood cells were lysed with fluorescence activating cell sorter lysing solution. White blood cells were then washed and incubated with Fc block prior to staining with antibodies. The fluorescence-conjugated antibodies against CD14 (PerCP-Cy5.5), human leukocyte antigen-DR (HLA-DR) (PE), both from ebioscience (ebioscience, San Diego, CA), were used for fluorescence activating cell sorter analysis. Cells were incubated with these antibodies for 20 min at 4°C in the dark, and then cell were washed and resuspended in 300 μL of PBS before applied to the BD LSR2 flow cytometer (BD Biosciences, San Jose, CA). The raw data were analyzed with FlowJo software (FlowJo software Inc., Ashland, Ore).

Quantitative reverse transcription-polymerase chain reaction

Total RNA extraction and the subsequent first strand cDNA synthesis were prepared as previously described (17). Expression of SphK1 and SphK2 mRNA were assessed using relative quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (17). PCR reaction was performed in triplicate using

| Characteristics | Heath (n = 31) | ICU controls (n = 19) | Sepsis (n = 33) | P value |
|-----------------|----------------|---------------------|----------------|--------|
| Age (yr)        | 52.71 ± 13.82  | 48.47 ± 15.34       | 57.45 ± 14.12  | 0.09   |
| Sex, male (%)   | 21 (67.74%)    | 12 (63.16%)         | 27 (81.82%)    | 0.27   |
| APACHE II score | NA             | 9.74 ± 4.48         | 12.24 ± 6.07   | 0.19   |
| SOFA score      | NA             | 5.16 ± 4.14         | 7.88 ± 4.14    | 0.027  |
| Peritonitis     | NA             | NA                  | 21 (63.64%)    |        |
| Pneumonia       | 6 (18.18%)     | 2 (6.06%)           | 8 (18.18%)     |        |
| Urinary tract infections | 2 (6.06%) |  |  | |
| Others          | 4 (12.12%)     |  |  | |
| Microbe species | NA             | 14 (42.42%)         | 16 (48.48%)    | 0.32   |
| Escherichia coli| NA             | 6 (18.18%)          | 2 (6.06%)      |        |
| Staphylococcus aureus | 2 (6.06%) |  |  | |
| Klebsiella pneumoniae | 2 (6.06%) |  |  | |
| Pseudomonas aeruginosa | 2 (6.06%) |  |  | |
| Candida albicans | 2 (6.06%) |  |  | |
| Length of ICU stay | 1.89 ± 1.20 | 3.51 ± 3.10 | 6 (18.18%) | 0.075  |
| 28-day mortality | 0 (0)          | 3.51 ± 3.10         | 6 (18.18%)     | 0.075  |

Data are expressed as the mean ± SD or number (%) where applicable.

APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; NA, not applicable; SOFA, sequential organ failure assessment.
was detected by a luminometer (Molecular Devices, Sunnyvale, CA), and a by the addition of ATP. The reaction was then stopped by adding the ATP protein assay kit (Life Technologies, Grand Island, NY), equal amounts of 15 min. After determining the protein concentration using a bicinchoninic acid human SphK2 Forward primer-CGGTTGCTTCTATTGGTCAA
human SphK1 Forward primer-CTGGCAGCTTCTGATACCCAT
human β-actin Forward primer-AGGAAATCTGGCACCACACC
Reverse primer-AGGACGGTACAGGGATAGCA

**Western blot**

Samples were lysed in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA) and 15 μg of total lysate was resolved with 12% SDS-PAGE. Proteins were then transferred to PVDF membranes (Millipore, Billerica, MA). Membranes were blocked with 5% fat-free milk/PBS and blotted with antibodies against SphK1, SphK2, or β-actin (Cell Signaling, Boston, MA). Membranes were subsequently washed and incubated in HRP-conjugated secondary antibodies (Millipore, Billerica, MA), washed, and detected with enhanced chemiluminescence (Biological Industries, Kibbutz Beit-Haemek, Israel) and exposed to X-ray films. The resulting protein bands were analyzed with Image J software.

**SphK activity assay**

SphKs activity in the platelets was measured using Echelon’s Sphingosine Kinase Activity Assay kit (Echelon Biosciences, Salt Lake City, UT). In brief, cells were resuspended in ice-cold reaction buffer, and lysed with sonication and freeze/thaw cycles. Then the lysed cells were centrifuged at 10,000 g for 15 min. After determining the protein concentration using a bicinchoninic acid protein assay kit (Echelon Biosciences, Salt Lake City, UT). In brief, 100 μL of samples or sphingomyelinase standard was added to microtiter plate. The data in figures are presented as mean ± SD unless stated otherwise. A two-tailed unpaired t-test was used to compare differences in continuous variables between two groups. Multi-group comparisons were assessed using analysis of variance (ANOVA) followed by Bonferroni post hoc tests. Differences in categorical data between two groups were compared using Fisher exact test or Chi-squared test. Correlations were analyzed by using linear regression. Receiver operating characteristic curves were generated to determine sensitivity versus 1-specificity, and areas under the curve (AUC) were calculated to examine the sensitivity. All statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL) or Prism 6.0 (GraphPad software Inc., La Jolla, Calif) software, and P < 0.05 was considered statistically significant.

**RESULTS**

**Concentrations of plasma S1P and ceramide change oppositely in patients with sepsis**

Thirty-three septic patients, 19 ICU non-septic controls (including 8 traumas and 11 SAP) and 31 healthy controls with similar demographic characteristics were enrolled into the study. The plasma levels of S1P and ceramide were measured by high performance liquid chromatography-electrospray ionization tandem mass spectrometry/mass spectrometry after de-proteinization of serum with acetonitrile. Compared to those in healthy and ICU controls (101.35 ± 146.34 ng/mL in health, 954.48 ± 174.86 ng/mL in ICU controls), the plasma S1P levels were significantly decreased in septic patients (706.69 ± 139.66 ng/mL, P < 0.05) (Fig. 1A). In contrast, the septic patients had significantly increased ceramide levels (47.17 ± 20.63 ng/mL, P < 0.001) when compared to the controls (20.65 ± 11.96 ng/mL in health, 26.61 ± 16.7 ng/mL in ICU controls) (Fig. 1B). Moreover, S1P levels were negatively associated with the ceramide levels in the septic patients (regression coefficient (r) = −0.36, P < 0.05, Fig. 1C).

**Plasma S1P and ceramide concentrations are linked to disease severity and immune status**

SOFA score is a particularly useful predictor of disease severity in critically ill patients (19). Linear regression analysis revealed a strong inverse correlation between SOFA scores and plasma S1P levels with a regression coefficient (r) of −0.50 (P < 0.01; Fig. 2A), and a strong positive correlation between

| Gene      | Sequence (from 5’ to 3’) |
|-----------|--------------------------|
| Human SphK1 | Forward primer-CTGGCAGCTTCTGATACCCAT |
| Human SphK2 | Forward primer-CGTTGCTTCTGATACCAC |
| Human β-actin | Forward primer-AGGAAATCTGGCACCACACC |
|           | Reverse primer-AGGACGGTACAGGGATAGCA |

**Neutral sphingomyelinase activity assay**

Neutral sphingomyelinase (N-SMase) activity in the platelets was measured using Echelon’s Sphingosine Kinase Activity Assay kit (Echelon Biosciences, Salt Lake City, UT). It is an enzyme-coupled assay that measures sphingomyelinase activity in biological samples through the downstream production of choline. Briefly, 100 μL of reaction mixture was added to each well of microtiter plate, then 100 μL of sphingomyelinase standard was added to microtiter plate. After incubating the microtiter plate at 37°C for 4 h with shaking, the absorbance was detected at 595 nm using a microplate reader (Molecular Devices, Sunnyvale, CA). The absorbance signal is positively correlated with the kinase activity.

**Statistical analysis**

The data in figures are presented as mean ± SD unless stated otherwise. A two-tailed unpaired t-test was used to compare differences in continuous variables between two groups. Multi-group comparisons were assessed using analysis of variance (ANOVA) followed by Bonferroni post hoc tests. Differences in categorical data between two groups were compared using Fisher exact test or Chi-squared test. Correlations were analyzed by using linear regression. Receiver operating characteristic curves were generated to determine sensitivity versus 1-specificity, and areas under the curve (AUC) were calculated to examine the sensitivity. All statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL) or Prism 6.0 (GraphPad software Inc., La Jolla, Calif) software, and P < 0.05 was considered statistically significant.

**Fig. 1.** S1P and ceramide concentrations in plasma from the studied patients. S1P (A) and ceramide (B) concentrations in plasma from different groups. n = 31 for healthy controls, n = 19 for ICU critical control, and n = 33 for sepsis patients. The data are shown as the mean ± SD and were analyzed by one-way ANOVA with Bonferroni corrections for multiple comparisons. (C) Correlation of S1P levels with ceramide levels in the septic patients (r = −0.36, P < 0.05). The data were analyzed by using linear regression analysis with 95% confidence line. *P < 0.05, **P < 0.001. ICU, intensive care unit; S1P sphingosine-1-phosphate.
SOFA scores and plasma-ceramide levels with a regression coefficient \((r) = 0.58\) \((P < 0.001; \text{Fig. 2B})\).

Previous studies have documented that some septic patients have severe immune alterations and are at high risk of death or nosocomial infection. Down-regulation of HLA-DR on circulating monocytes is one of the surrogate markers for immune alteration (20, 21). To demonstrate that levels of plasma S1P and ceramide were linked not only to disease severity but also to immune status, septic patients were classified into two groups according to the expression of HLA-DR on circulating monocytes. In those patients with decreased expression of HLA-DR (<30%), S1P expression was significantly lower than that in patients with higher HLA-DR expression (>30%), whereas ceramide showed the opposite trend (Fig. 2C and D). Integrated analysis of plasma S1P and ceramide predict septic mortality with high accuracy.

To compare the potential of various clinical parameters with S1P and ceramide as to indicate mortality within patients with sepsis, an ROC analysis with S1P, ceramide, ceramide/S1P ratio, SOFA score, and HLA-DR was performed. Among all parameters tested, plasma S1P and the ceramide/S1P ratio emerged as the better powerful indicators of lethality, with AUC values of 0.94 for S1P and 0.95 for ceramide/S1P ratio (Fig. 3). The ROC curves for ceramide, SOFA, and HLA-DR were similar, with AUC values between 0.82 and 0.85.

Platelets release S1P and contribute to plasma S1P levels during sepsis

It has been known that platelets, which are primarily involved in hemostasis, are decreased in septic individuals, and the more profound the thrombocytopenia, the more severe the sepsis and the greater the mortality (22, 23). In our current study, the platelet count in the septic patients and ICU controls are comparable, both of which are lower than that in the healthy (Fig. 4AA). So, thrombocytopenia may not distinguish sepsis from ICU controls.

It also should be noted that, during coagulation, S1P released from platelets contributed to total plasma-S1P levels (24, 25).
Rapid and profound depletion of plasma S1P during systemic anaphylaxis rendered platelet-derived S1P essential for survival (26). To assess whether platelet is responsible for the alterations of plasma S1P and ceramide concentrations in septic patients, we evaluated the platelet sphingosine kinases (SphKs) and N-SMase activities in the studied patients. As expected, the SphKs activity in the 33 septic patients was significantly lower than in the health and ICU controls (Fig. 4B). The SphKs activities detected from the health and ICU controls were comparable (Fig. 4B). Linear regression analysis revealed SphKs activities were positively associated with the plasma S1P concentration of the septic patients ($r = -0.41, P = 0.02$, Fig. 4C). Contrarily, compared with the health and ICU controls, the N-SMase activity was significantly increased in septic patients (Fig. 4D). However, Linear regression analysis revealed the increased N-SMase activity was not the major reason for the increased plasma ceramide in septic patients ($P = 0.63$, Fig. 4E).

**Reduced platelet SphK1 expression leads to the decreased SphKs activities in septic patients**

To explore the reason of the decreased platelet SphKs activities in septic patients, we further evaluated the platelet SphK1/2 mRNA and protein levels in the studied patients. The mRNA level of SphK1 was ∼15-fold higher than SphK2 in platelets isolated from the health controls (Fig. 5A). Compared with the health and ICU controls, SphK1 mRNA was significantly lower from septic patients (Fig. 5B). Platelet SphK1 protein expression was also significantly decreased in patients with sepsis (Fig. 5D). However, the SphK2 mRNA and protein levels were comparable in those study participants (Fig. 5, C and D).

**DISCUSSION**

The main findings of our current study are that patients with sepsis-3 have decreased plasma S1P but increased plasma-ceramide concentrations. This phenomenon was also confirmed in the patients with sepsis-1 (Supplemental Table 1 and Supplemental Figure 1, http://links.lww.com/SHK/A793). Integrated analysis of plasma S1P and ceramide predict septic mortality with high accuracy. Furthermore, reduced plasma S1P levels may result from lower platelet SphK1 expression and SphKs activity during sepsis.

Recognizing sepsis early improves patient outcomes (8). The commonly used plasma biomarkers of inflammation or infection, such as procalcitonin and C-reactive protein, identify several conditions characterizing sepsis and thus help to confirm the diagnosis (27). However, these biomarkers have limited use in preventing sepsis-related multi-organ dysfunction syndrome. Ceramide and S1P have emerged as a new class of lipid modulators of various cell functions (10). Ceramide...
is shown to mediate many cellular events including growth arrest, differentiation, and apoptosis (11, 13). In contrast to ceramide, S1P has been implicated in mediating cell proliferation and antagonizing ceramide-mediated apoptosis (15). In patients with sepsis, we found plasma S1P was approximately 30% lower than in controls. In contrast, ceramide level had nearly 2-fold increase in septic patients. Linear regression analysis revealed a strong inverse correlation between SOFA scores and plasma S1P levels, and a strong positive correlation between SOFA scores and plasma-ceramide levels. These results suggested that the imbalance of ceramide/S1P ratio creates the SIRS and subsequent organ dysfunction during sepsis.

The degree of HLA-DR expression or the response of leukocytes to pathogenic stimuli reflects the patients’ host response (28). The expression of HLA-DR in health is up to 90% (the rate of HLA-DR positive monocytes/total monocytes). Down-regulation of HLA-DR on the surface of circulating monocytes is generally accepted as a reliable marker for an immune dysfunction in septic patients. Importantly, lowered expression of $\leq 30\%$ HLA-DR has been associated with the severity of sepsis, especially with fatal outcome and septic shock (28–30). Therefore, a cutoff of 30% HLA-DR expression was used to stratify the septic patients. In present study, in those with decreased expression of HLA-DR ($<30\%$), S1P levels were significantly reduced than those in patients with higher HLA-DR expression ($>30\%$). However, ceramide showed the opposite trend. The imbalance of ceramide/S1P ratio may induce the cycle arrest and apoptosis of immune cells, and then promotes the subsequent immune dysfunction.

Platelets are potent immune modulators and effectors (31). Platelets abundantly express SM at the cell surface, which is thought to be an important source of plasma S1P and ceramide (13, 14). The amount of S1P released from platelets is much higher than that from other cell types, as it possesses a highly active SphKs and do not have S1P lyase or S1P phosphatase activity (32, 33). During coagulation and systemic anaphylaxis, platelets release S1P and contribute to total circulating S1P levels and survival (25, 26). In our current study, we found SphK1 is the major SphKs in human platelets. Compared with the health and ICU controls, SphK1 expression and its activity are significantly decreased in platelets from septic patients. Linear regression analysis revealed SphKs activity in platelet was positively associated with the plasma S1P concentration of the septic patients. The SphK1 mRNA and protein responses were nicely correlated in platelets. Therefore, measures of genetically up-regulate the SphK1 mRNA content in platelet maybe a potential way to increase the protein translation and rescue the dysfunctional platelets during sepsis.

N-SMase is a key SMase for ceramide generation that is involved in regulating cellular stress responses and exosome-mediated intercellular communication (34). In our current study, compared with the health and ICU controls, the platelet N-SMase activity was significantly increased in septic patients. Tani et al. demonstrated that treatment with bacterial SMase results in sphingosine generation at the platelet extracellular surface (24). Schissel et al. also showed the secretory sphingomyelinase activity, which mediates the extracellular degradation of SM to ceramide during inflammation (35). So, the sSMPase-mediated ceramide production may be associated
with the development of sepsis. That may be the reason why linear regression analysis revealed the increased N-SMase activity in platelet was not associated with the increased plasma ceramide in septic patients. In summary, our study demonstrates that plasma S1P is negatively correlated with ceramide in septic patients and is more powerful than ceramide as a predictor of sepsis mortality. The events contributing to the decreased plasma S1P concentration, according to our findings, is depended on the dysfunctional platelets in SphK1 expression. This pilot study implies that pharmaceutical agents targeting platelets SphK1 may have beneficial value for septic patients.

REFERENCES

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al.: The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315(8):801–810, 2016.
2. van der Poll T, van de Weerdonk FL, Scicluna BP, Netea MG: The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 2017;17(5):407–420, 2017.
3. Shankar-Hari M, Ambler M, Mahalingasivam V, Jones A, Rowan K, Rubenfeld GD: Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies. Crit Care 2010;14, 2016.
4. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, Kadri SS, Shankar-Hari M, Ambler M, Mahalingasivam V, Jones A, Rowan K, Rubenfeld GD, Delaney A, Gimbel E, Grieve RD, et al.: Early, goal-directed therapy for septic shock: a patient-level meta-analysis. N Engl J Med 2016;375(23):2223–2234, 2017.
5. Rowan KM, Angus DC, Bailey M, Barnato AE, Bellomo R, Canter RR, Coats TJ, Delaney A, Gimbel E, Grieve RD, et al.: Early, goal-directed therapy for septic shock: a patient-level meta-analysis. N Engl J Med 2017;376(23):2282–2285, 2017.
6. Reinhart K, Daniels R, Kwissoon N, Machado FR, Schaechter RD, Finfer S. Recognising sepsis as a global health priority: a WHO resolution. N Engl J Med 2017;377(5):414–417, 2017.
7. Kaukonen KM, Bailey M, Bellomo R: Systemic inflammatory response syndrome criteria for severe sepsis. N Engl J Med 2017;377(9):881, 2015.
8. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2016;510(7503):58–67, 2014.
9. Deluca G, Fumaluzo G, Amati F, Signore L, Antonucci A, Trincieri V, Di Marzo L, Cifone MG: Ceramide concentrations in septic patients: a possible marker of multiple organ dysfunction syndrome. Crit Care Med 2016;44(11):2413–2417, 1999.
10. Vettorarazzi S, Bode C, Dejager L, Frappart L, Shelest E, Klassen C, Tadogian D, Reichardt HM, Schneider M, et al.: Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of SphK1. Nat Commun 6:7796, 2015.
11. Tani M, Ito M, Igarashi Y: Ceramide/sphingosine-1phosphatase metabolism on the cell surface and in the extracellular space. Cell Signal 2016;29(2):229–237, 2007.
12. Chick PK, Tuszyński GP, Vander Voort PW: Human platelet cytoskeletons: specific content of glycolipids and phospholipids. Blood 1983;61(1):163–166, 1983.
13. Ogretmen B: Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 2015;15(1):33–50, 2018.
14. Hou JC, Chen QX, Wu XL, Zhao DY, Reuveni H, Lichten T, Xu ML, Hu H, Hoef A, Ben-Sasson SA, et al.: S1P3 signaling drives bacterial killing and is required for survival in bacterial sepsis. Am J Respir Crit Care Med 2017;196(2):1559–1570, 2017.
15. Hou JC, Chen QX, Zhang K, Cheng BL, Xie GH, Wu XL, Luo C, Chen L, Liu H, Zhao B, et al.: Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis. Anesthesiology 2015;123(2):409–422, 2015.
16. Mayer JL, Beardsley DS: Varicella-associated thrombocytopenia: autoantibodies against platelet surface glycoprotein V. Pediatr Res 1996;40(4):615–619, 1996.
17. Jones AE, Trezziak S, Kline JA: The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 2009;37(5):1649–1654, 2009.
18. Drewry AM, Abbordeey EA, Murray ET, Beiter ER, Walton AH, Hall MW, Hotchkiss RS: Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit Care 2010;13:346, 2010.